title: Nuclear survivin expression predicts poorer prognosis in glioblastoma.
abstract: Survivin is a member of the inhibitor of apoptosis family, and is expressed in various malignant tumors. Survivin overexpression has been reported to be a poorer prognostic factor in various malignancies. However, the prognostic value of survivin expression in patients with glioblastoma is still controversial. Therefore, in this study the role of survivin as a predictor for survival was investigated in patients with glioblastoma. Tissue specimens were obtained from 66 patients with glioblastoma treated with radiotherapy. Survivin expression was detected by an immunohistochemical method. Nuclear and cytoplasm survivin scores were defined by using the cell positivity and staining intensity. The scores were defined as follows, 0 (no staining), 1 (less than 50% of cell positivity and any staining), 2 (more than 50% of cell positivity and weak to moderate intensity) and 3 (more than 50% of cell positivity and strong intensity). The correlation between survivin scores and the overall survival rate was evaluated. Nuclear and cytoplasm survivin staining were noted in 47 and 58 patients, respectively. The number of patients with nuclear survivin score of 0, 1, 2 and 3, were 19 (28.8%), 26 (39.4%), 9 (13.6%) and 12 (18.2%), respectively. The 3-year overall survival rate of the nuclear survivin score 3 was 0%, significantly lower than the 11.6% of the nuclear survivin score </=2 (P = 0.0003). Cytoplasm survivin score did not correlate with the prognosis. Nuclear survivin expression may be a useful biomarker for predicting prognosis in patients with glioblastoma.
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, Japan.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Shirai
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Kuniyuki
authors.initials: K
authors.lastname: Oka
authors.forename: Shin-ei
authors.initials: SE
authors.lastname: Noda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Katoh
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Jun
authors.initials: J
authors.lastname: Itoh
authors.forename: Hideaki
authors.initials: H
authors.lastname: Itoh
authors.forename: Shogo
authors.initials: S
authors.lastname: Ishiuchi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Sakurai
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
mesh_terms: D000328:Adult; D000368:Aged; D002467:Cell Nucleus / Q000378:metabolism / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology / Q000528:radiation effects; D005909:Glioblastoma / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D011878:Radiotherapy / Q000379:methods; D000077022:Survivin; D013997:Time Factors
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D000077022:Survivin